Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Rapid Affordable Microbiota Analysis at the point of Need

Project description

Real-time microbiota analysis for precision medicine

The rise of precision medicine and the ongoing destruction of microbiological ecosystems due to global warming have highlighted the need for rapid, real-time microbiota analysis. Current methods, such as culture, metagenomics, and proteomics, are unsuitable for immediate use at critical moments. This hampers timely interventions, particularly in high-stakes areas like healthcare and organic production. As the microbiota market expands rapidly, there is a growing demand for faster, more efficient solutions. The EIC-funded RAMAN project aims to address this need by developing a device for Rapid, Affordable Microbiota Analysis at the point of Need (RAMAN). This device provides comprehensive results in just 10 minutes, focusing on crucial applications like vaginal and fermentation microbiota.

Objective

With the pressing demand of precision medicine and the catastrophic damage to microbiological ecosystems following organic processing and global warming, there is a critical need to rapidly characterise microbiota directly at the point of need and observe their potential drifts in real time to correct them in a timely manner. We recently observed an explosive growth of the microbiota market (+30% CAGR) with analyses relying on culture, metagenomics, or proteomics. However, all the available solutions are far too long to process and unadapted to operate at the point of need.
BforCure has developed the first device ever enabling Rapid, Affordable Microbiota Analysis at the point of Need (RAMAN) for a comprehensive microbiota test result in just 10 min.
The RAMAN project aims at 1) Maturing technologies from TRL4 to TRL 6, 2) developing two microbiota universal tests for vaginal microbiota (critical during deliveries with 4% of problematic births worldwide) and fermentation microbiota (responsible for the loss of up to 25% of the production with organic transformation).
Strong demand from end-users and increasing legislation on the spread of microbiological risks make this an ideal time for our project. BforCure has developed a set of 4 breakthrough micro-nano-bio technologies that, once combined, unlock for the first time the possibility of bringing microbiota tests at the Point of Need giving a strong competitive advantage on a 11.9B market.
BforCure is a dynamic company which has already demonstrated the successful development and commercialization of a microfluidic medical device in just 3 years. Our direct contact with the market and our agility of development make us the perfect team to build market-driven products with disruptive technologies which is crucial to create new markets.
Once industrialised, our solution will enable BforCure and its customers to harness the power of the microbiota in many other contexts in health, agri-food industry, and wellness.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.

You need to log in or register to use this function

Coordinator

BFORCURE
Net EU contribution
€ 2 466 223,75
Address
14 RUE DE LA BEAUNE
93100 Montreuil
France

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Ile-de-France Ile-de-France Seine-Saint-Denis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 2 466 223,75